San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
This article was originally published in PharmAsia News
Executive SummaryHONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.
You may also be interested in...
Who’s on first in China? That might be the a good question for AstraZeneca’s chief Pascal Soriot after the CEO of Pfizer also went out of his way to highlight second quarter success in the Middle Kingdom.